Author presents Nu Skin Enterprises as potentially undervalued based on low valuation multiples and recent earnings beat, while acknowledging execution risks.
NUS — WATCH The author highlights NUS's cheap valuation: trailing P/E 4.49x, forward P/E 6.93x, EV/EBITDA 2.70x, and price/book 0.60x, with Q4 revenue of $364M and EPS of $0.34 beating estimates. Peers trade at 15-25x forward while NUS is under 7x with good cash flow and lower leverage after the $250M affiliate platform sale. The author sees potential value but notes execution risks, framing the question as whether the stock is undervalued or a value trap.
Peers at 15-25x fwd; NUS sub-7x with good cash flow, lower leverage post-sale.